Zyxel Communications Redefines Connectivity at Mobile World Congress 2025
Zyxel Communications, an industry-leading provider of secure broadband networking, internet access, and connected home products, will showcase its latest industry-leading broadband products and solutions at Mobile World Congress 2025.
Visit booth 5I20 in hall 5 to discover how Zyxel is revolutionizing connectivity with its innovative solutions: 5G FWA, Wi-Fi 7 and Wi-Fi 6 portfolio including our Red Dot Award-winning design. Visitors can also experience 10G Fiber, Next-Generation Edge Optical Node, and Zyxel’s OPAL 3.0 – our next-generation middleware platform powered by prpl.
“The broadband industry is more collaborative – and competitive – than ever, with industry leaders constantly raising the bar for innovation and excellence,” said Nicolai Redfern, EMEA Product Director at Zyxel Communications. “As we bolster our presence at global events, Mobile World Congress provides a unique opportunity to showcase what we do best – keeping service providers ahead of the competition. Visitors to our booth will hear from Zyxel customers about how our newest technologies are shaping the future of connectivity and driving success for their businesses.”
Zyxel’s MWC display will be Europe’s first look at the Zyxel 2025 product lineup:
- Reliable Wi-Fi 7: Get to know the new 10G Ethernet Tri-Band and Dual-Band Gateway additions to our portfolio and meet Zyxel’s OPAL 3.0, powered by prpl. Zyxel’s Wi-Fi 7 solutions help service providers deliver high-performing connectivity to its subscribers while opening the door to new revenue-generating services.
- Seamless XGS-PON: Powered by industry-leading 10G Ethernet to XGS-PON bridge ONT devices. Whether it’s GPON 2.5G, XGS-PON or XGS-PON with VoIP, Zyxel’s cutting-edge solutions make network migration easy to meet subscribers’ ever-increasing bandwidth demands.
- 5G FWA, inside and out: Zyxel is showcasing its top Wi-Fi 7 enabled indoor and outdoor 5G routers. Designed for deployment flexibility, these routers enable service providers to deliver high-capacity and ultrafast broadband services to their customers.
- 10G Fiber and beyond: Zyxel’s Whitebox OLTs, switches and bridge options – ranging from GPON to XGS-PON ONTs – are an excellent fit for service providers looking to open new revenue opportunities and gain competitive advantages offered by faster network speeds. And, have a look at our next generation edge node.
To schedule a meeting with a Zyxel expert at Mobile World Congress 2025 or for a detailed invitation to our booth, visit: https://www.zyxel.com/service-provider/global/en/events/mwc-2025
About Zyxel
Zyxel Communications delivers technological innovations and has connected the world to the internet for more than 35 years. Whether establishing access through fixed or mobile broadband solutions, Zyxel Communications offers a comprehensive and flexible portfolio of products that are keeping service providers ahead of the competition.
For more information, please follow us on LinkedIn and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220751459/en/
Contacts
Grant Tucker
Arketi Group
gtucker@arketi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom